Floatz logo

Sertraline

Pervasive Development Disorders

Washington University School of MedicineSmall moleculePhase 4 / ApprovedDormant
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Pervasive Development Disorders cohort.

Asset / SponsorPhaseRating
Risperdal
Washington University School of Medicine
Phase 4BBB
Olanzapine
Washington University School of Medicine
Phase 4BB
Cipralex
Washington University School of Medicine
Phase 4BB
CITALOPRAM
Washington University School of Medicine
Phase 4BB
Calcium folinate pentahydrate
University of Arkansas
Phase 2CCC

Same molecule, other indications

Sertraline is also rated in:

anxiety disorderDormant
BBB
Indicative ·
76 / 100
View asset →
Bipolar I DisorderDormant
BBB
Indicative ·
76 / 100
View asset →
depressive disorderDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →